Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Kathleen W Zhang"'
Autor:
Andrew Perry, Francis Loh, Luigi Adamo, Kathleen W Zhang, Elena Deych, Randi Foraker, Douglas L Mann
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0248317 (2021)
BackgroundPatients with heart failure (HF) with recovered ejection fraction (HFrecEF) are a recently identified cohort that are phenotypically and biologically different from HFrEF and HFpEF patients. Whether there are unique phenotypes among HFrecEF
Externí odkaz:
https://doaj.org/article/c95049efe53248e7ba9d22c837369014
Autor:
Jesus Jimenez, Nicolas Kostelecky, Joshua D. Mitchell, Kathleen W. Zhang, Chieh-Yu Lin, Daniel J. Lenihan, Kory J. Lavine
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract Background Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well defined. Additionally
Externí odkaz:
https://doaj.org/article/5462eb27bdc04566acb51ffc4305cb85
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Coronary heart disease (CHD) is a leading cause of morbidity and mortality for breast cancer survivors, yet the joint effect of adverse cardiovascular health (CVH) and cardiotoxic cancer treatments on post-treatment CHD and death
Externí odkaz:
https://doaj.org/article/a31ff7aec9504beeaf8ee0e69c2114aa
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 3, Pp 438-448 (2019)
Summary: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyreti
Externí odkaz:
https://doaj.org/article/5d0882c5d2194fe89d5993ec273a7d22
Autor:
Douglas Kyrouac, Walter Schiffer, Brandon Lennep, Nicole Fergestrom, Kathleen W. Zhang, John Gorcsan, Daniel J. Lenihan, Joshua D. Mitchell
Publikováno v:
ESC Heart Failure, Vol 9, Iss 1, Pp 385-397 (2022)
ESC Heart Failure
ESC Heart Failure
Aims The accuracy of an apical‐sparing strain pattern on transthoracic echocardiography (TTE) for predicting cardiac amyloidosis (CA) has varied in prior studies depending on the underlying cohort. We sought to evaluate the performance of apical sp
Autor:
Michael G. Fradley, Adam C. Calaway, Arjun K. Ghosh, Daniel Addison, Brian C. Baumann, Lee Ponsky, Neal L. Weintraub, Jorge A. Garcia, Nihar R. Desai, Jennifer Cullen, Melissa A. Reimers, Courtney M. Campbell, Kathleen W. Zhang, Daniel J. Lenihan, Avirup Guha
Publikováno v:
Journal of Urology. 206:613-622
Purpose:The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known.Materials and Methods:We queried the U.S. Food and Drug Adminis...
Autor:
Srilakshmi Vallabhaneni, Henning Steen, Jose Alvarez-Cardona, Daniel J. Lenihan, Joshua D. Mitchell, Kathleen W. Zhang, Pamela K. Woodard
Publikováno v:
The International Journal of Cardiovascular Imaging. 37:3003-3017
The purpose of this review is to provide an overview of the essential role that cardiovascular magnetic resonance (CMR) has in the field of cardio-oncology. Recent findings: CMR has been increasingly used for early identification of cancer therapy re
Autor:
John Gorcsan, George A. Heberton, Peter Huntjens, Brian A. Van Tine, Joshua D. Mitchell, Peter Oppelt, Jose Alvarez-Cardona, Ronald J. Krone, Michele Landeau, Richa Rathore, Fei Wan, Justin M. Vader, Angela C. Hirbe, Kathleen W. Zhang, Yoku Soyama, Daniel J. Lenihan, Shellie Berry, Ashley Frith
Publikováno v:
Clinical Cancer Research. 27:3854-3860
Purpose: To report the interim analysis of the phase II single-arm noninferiority trial, testing the upfront use of dexrazoxane with doxorubicin on progression-free survival (PFS) and cardiac function in soft-tissue sarcoma (STS). Patients and Method
Publikováno v:
International Journal of Cardiology. 322:177-182
Background Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. Objectives We so
Autor:
Kathleen W. Zhang, Jose Alvarez-Cardona, Daniel J. Lenihan, Michael J. Fisch, Vlad G. Zaha, Joshua D. Mitchell
Publikováno v:
JACC: CardioOncology. 2:791-794